

WHAT IS CLAIMED IS:

1. A medical device comprising:
an implantable structure; and
5 a histone deacetylase inhibitor, in therapeutic dosages,
releasably affixed to the implantable structure for the treatment of restenosis
following vascular injury.

- 10 2. The medical device according to Claim 1, wherein the
implantable structure comprises a stent.

- 15 3. The medical device according to Claim 1, wherein the
implantable structure comprises a stent-graft.

4. The medical device according to Claim 1, wherein the histone
deacetylase inhibitor comprises trichostatin A.

- 20 5. The medical device according to Claim 1, further comprising a
polymeric coating, the histone deacetylase inhibitor being incorporated into
the polymeric coating.

6. A medical device comprising:
an implantable structure;
a histone deacetylase inhibitor, in therapeutic dosages,
25 releasably affixed to the implantable structure for the treatment of restenosis
following vascular injury; and
an anti-proliferative, in therapeutic dosages, releasably affixed to
the implantable structure for the treatment of restenosis following vascular
injury.

- 30 7. The medical device according to Claim 6, wherein the
implantable structure comprises a stent.

8. The medical device according to Claim 6, wherein the implantable structure comprises a stent-graft.

9. The medical device according to Claim 6, wherein the histone deacetylase inhibitor comprises trichostatin A.
5

10. The medical device according to Claim 9, wherein the anti-proliferative comprises rapamycin.

10 11. The medical device according to Claim 10, further comprising a polymeric coating, the histone deacetylase inhibitor and the anti-proliferative being incorporated into the polymeric coating.

15 12. A medical device comprising:
a delivery structure; and
a histone deacetylase inhibitor, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

20 13. A medical device comprising:
a delivery structure;
a histone deacetylase inhibitor, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury; and
25 an anti-proliferative, in therapeutic dosages, operatively associated with the delivery structure for the treatment of restenosis following vascular injury.

14. A method for treating restenosis comprising the local administration of a therapeutic dose of a histone deacetylase inhibitor.